inclusion criteria: * male or female subjects of ≥ 18 years old with body mass index (bmi) ≥ 18.5 and ≤ 30 at the screening visit. * the subject can provide with informed consent and signs and dates a written informed consent form (icf) prior to the initiation of any trial procedures. * they must be able to understand and follow trial-related instructions. * they must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial. * negative hiv antibody when screening. * axillary temperature ≤ 37.0ºc. * negative in nucleic acid screening of sars-cov-2. * negative in antibodies (igg and igm) screening of sars-cov-2. * no imaging features of covid-19 in chest ct. * there were no significant abnormalities in blood routine, blood biochemistry, coagulation function and urine routine, or no clinical significance was determined by doctors (including white blood cell count, lymphocyte count, neutrophil count, platelet, hemoglobin, glutamic pyruvic transaminase alt, glutamic oxaloacetic transaminase ast, total bilirubin, fasting blood glucose, creatinine, prothrombin time, partially activated prothrombin time, urine protein, urine red blood cells). * healthy subjects who have been examined by medical history, physical examination and clinical examination are in accordance with the immunization of this vaccine.

inclusion criteria: * male or female subjects of ≥ 18 years old with body mass index (bmi) ≥ 18.5 and ≤ 30 at the screening visit. * the subject can provide with informed consent and signs and dates a written informed consent form (icf) prior to the initiation of any trial procedures. * they must be able to understand and follow trial-related instructions. * they must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial. * negative hiv antibody when screening. * axillary temperature ≤ 37.0ºc. * negative in nucleic acid screening of sars-cov-2. * negative in antibodies (igg and igm) screening of sars-cov-2. * no imaging features of covid-19 in chest ct. * there were no significant abnormalities in blood routine, blood biochemistry, coagulation function and urine routine, or no clinical significance was determined by doctors (including white blood cell count, lymphocyte count, neutrophil count, platelet, hemoglobin, glutamic pyruvic transaminase alt, glutamic oxaloacetic transaminase ast, total bilirubin, fasting blood glucose, creatinine, prothrombin time, partially activated prothrombin time, urine protein, urine red blood cells). * healthy subjects who have been examined by medical history, physical examination and clinical examination are in accordance with the immunization of this vaccine.

inclusion criteria: - male or female subjects of ≥ 18 years old with body mass index (bmi) ≥ 18.5 and ≤ 30 at the screening visit. - the subject can provide with informed consent and signs and dates a written informed consent form (icf) prior to the initiation of any trial procedures. - they must be able to understand and follow trial-related instructions. - they must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial. - negative hiv antibody when screening. - axillary temperature ≤ 37.0ºc. - negative in nucleic acid screening of sars-cov-2. - negative in antibodies (igg and igm) screening of sars-cov-2. - no imaging features of covid-19 in chest ct. - there were no significant abnormalities in blood routine, blood biochemistry, coagulation function and urine routine, or no clinical significance was determined by doctors (including white blood cell count, lymphocyte count, neutrophil count, platelet, hemoglobin, glutamic pyruvic transaminase alt, glutamic oxaloacetic transaminase ast, total bilirubin, fasting blood glucose, creatinine, prothrombin time, partially activated prothrombin time, urine protein, urine red blood cells). - healthy subjects who have been examined by medical history, physical examination and clinical examination are in accordance with the immunization of this vaccine.

inclusion criteria: - male or female subjects of ≥ 18 years old with body mass index (bmi) ≥ 18.5 and ≤ 30 at the screening visit. - the subject can provide with informed consent and signs and dates a written informed consent form (icf) prior to the initiation of any trial procedures. - they must be able to understand and follow trial-related instructions. - they must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial. - negative hiv antibody when screening. - axillary temperature ≤ 37.0ºc. - negative in nucleic acid screening of sars-cov-2. - negative in antibodies (igg and igm) screening of sars-cov-2. - no imaging features of covid-19 in chest ct. - there were no significant abnormalities in blood routine, blood biochemistry, coagulation function and urine routine, or no clinical significance was determined by doctors (including white blood cell count, lymphocyte count, neutrophil count, platelet, hemoglobin, glutamic pyruvic transaminase alt, glutamic oxaloacetic transaminase ast, total bilirubin, fasting blood glucose, creatinine, prothrombin time, partially activated prothrombin time, urine protein, urine red blood cells). - healthy subjects who have been examined by medical history, physical examination and clinical examination are in accordance with the immunization of this vaccine.